PANDION THERAPEUTICS HOLDCO LLC

Profile

Company Names

PANDION THERAPEUTICS HOLDCO LLC

Addresses

610 MAIN STREET, CAMBRIDGE, MA 02139

Phone Numbers

617-393-5924

 

Entity Type:

LIMITED LIABILITY COMPANY

Industry:

BIOTECHNOLOGY

Year Incorporated:

2018

State Incorporated:

DELAWARE

Total Amount Raised:

$39,999,997.00

Number of Funding Rounds:

1
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
1
2020-03-23 
$39,999,997.00 
$79,999,994.00 
$39,999,997.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
DANIEL 
 
BECKER 
DIRECTOR
WATCHWITH, INC.   |  NEURANA PHARMACEUTICALS, INC.   |  PRINCIPIA BIOPHARMA INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  DTX PHARMA, INC.   |  DAY ONE BIOPHARMACEUTICALS HOLDING CO LLC   |  MATCHPOINT THERAPEUTICS INC.   |  ARETEIA THERAPEUTICS, INC.
JILL 
 
CARROLL 
DIRECTOR
VASCULOX, INC.   |  TIOMA THERAPEUTICS, INC.   |  ARCELLX, INC.   |  NKARTA, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  ODYSSEY THERAPEUTICS, INC.   |  AVALYN PHARMA INC.   |  AIRNEXIS THERAPEUTICS, INC.
ALAN 
L. 
CRANE 
DIRECTOR
CERULEAN PHARMA INC.   |  VACCINEX, INC.   |  KSQ THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC
DONALD 
 
FRAIL 
DIRECTOR
PANDION THERAPEUTICS HOLDCO LLC
CHRISTOPHER 
 
FUGLESANG 
DIRECTOR
CIVI BIOPHARMA HOLDINGS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  SHORELINE BIOSCIENCES, INC.
VIKAS 
 
GOYAL 
EXECUTIVE OFFICER
CALCIMEDICA INC   |  MACROLIDE PHARMACEUTICALS, INC.   |  MORPHIC HOLDING, LLC   |  SPERO THERAPEUTICS, LLC   |  PANDION THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC
RAHUL 
 
KAKKAR 
EXECUTIVE OFFICER, DIRECTOR
PANDION THERAPEUTICS HOLDCO LLC   |  ATTRALUS, INC.   |  EGENESIS, INC.
MITCHELL 
 
MUTZ 
DIRECTOR
AMPLYX PHARMACEUTICALS, INC.   |  PURIGEN BIOSYSTEMS, INC.   |  PANDION THERAPEUTICS, INC.   |  GOOD THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  BONUM THERAPEUTICS, INC.   |  EPIBIOLOGICS, INC.   |  OMNIOX, INC.
CARLO 
 
RIZZUTO 
DIRECTOR
VENATORX PHARMACEUTICALS, INC.   |  QUENTIS THERAPEUTICS, INC.   |  PANDION THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  GRAPHITE BIO, INC.   |  CENTURY THERAPEUTICS, INC.   |  858 THERAPEUTICS, INC.   |  JNANA THERAPEUTICS INC.   |  NEXO THERAPEUTICS, INC.   |  VERSANT VOYAGEURS III, L.P.   |  VERSANT VOYAGEURS III (CANADA), L.P.   |  VERSANT VANTAGE III, L.P.   |  VERSANT VANTAGE III (CANADA), L.P.   |  VERSANT VENTURE CAPITAL IX, L.P.   |  VERSANT VENTURE CAPITAL IX (CANADA), L.P.   |  PEP2TANGO THERAPEUTICS, INC.
NANCY 
 
STAGLIANO 
DIRECTOR
CYTOMX THERAPEUTICS, LLC   |  CYTOMX THERAPEUTICS, INC.   |  BIOASIS TECHNOLOGIES INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  LATIGO BIOTHERAPEUTICS, INC.   |  STAR THERAPEUTICS LLC
JO 
 
VINEY 
EXECUTIVE OFFICER
PANDION THERAPEUTICS, INC.   |  PANDION THERAPEUTICS HOLDCO LLC   |  FINCH THERAPEUTICS GROUP, INC.
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2020-04-07
D
Link
BIOTECHNOLOGY 
 
DECLINE TO DISCLOSE 
Equity 
2020-03-23 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#